Hilary Jean McKenna

This inventor holds 7 USPTO granted patents and 2 published patent applications. Top assignees: Immunex Corporation, Innunex Corporation. Active years: 2002-2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hilary Jean McKenna. Retrieved from https://idiyas.com/inventor/hilary-jean-mckenna

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 2)

% Patents Active = 57.1

Average Co-Inventor Count = 3.7

ph-index = 5

Forward Citations = 114(Granted Patents)

Company Filing History:

Years Active: 2002-2013

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8444979 - Antibodies that inhibit TSLP activity (2013-05-21),

2. 7786271 - Antibodies that inhibit TSLP activity (2010-08-31),

3. 7405058 - Human TSLP polynucleotides (2008-07-29),

4. 7304144 - Antibodies binding to human TSLP Polypeptides (2007-12-04),

5. 7150992 - Methods of preparing dendritic cells with flt3-ligand and antigen (2006-12-19),

6. 6555520 - Human TSLP DNA and polypeptides (2003-04-29),

7. 6497876 - Method of stimulating an immune response with activated dendritic cells (2002-12-24),

Title: Innovator Hilary Jean McKenna: Pioneering Antibody Development in Seattle

Introduction: Hilary Jean McKenna is an influential inventor based in Seattle, WA, who has made significant contributions to the field of biotechnology. With a portfolio of seven patents, McKenna has focused his research on innovative solutions in the medical and therapeutic domains, particularly in the development of antibodies.

Latest Patents: Among his notable inventions, McKenna's latest patents include groundbreaking work on antibodies that inhibit TSLP (thymic stromal lymphopoietin) activity. These inventions are directed towards purified and isolated novel TSLP polypeptides, alongside the nucleic acids encoding these polypeptides. The patents also encompass processes for the production of recombinant forms of TSLP polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from them, and various applications of these innovative findings.

Career Highlights: McKenna has showcased his expertise while working at prominent companies such as Immunex Corporation and Innunex Corporation. His professional journey reflects a dedication to advancing medical research and therapeutics through innovative inventions.

Collaborations: Throughout his career, McKenna has collaborated with esteemed professionals like John Ernest Sims and Stewart D. Lyman. These partnerships have fostered creativity and synergy, further enhancing the impact of his work in biotechnology.

Conclusion: Hilary Jean McKenna stands out as a visionary inventor whose contributions continue to shape the future of medical treatments through his patented innovations. His commitment to research and development in therapeutic technologies reinforces the vital role of inventors in advancing healthcare solutions.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

2 patents pending: